enGene (NASDAQ:ENGN) Issues Earnings Results

enGene (NASDAQ:ENGN) announced its quarterly earnings results on Monday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.11, Zacks reports.

Here are the key takeaways from enGene’s conference call:

• Management attributes a combined effect of protocol amendments (T1 re‑resection, TA reinduction, routine biopsy) plus improved clinical execution for an estimated ≈21 percentage‑point improvement in the six‑month complete response rate.
• The program has received RMAT and CDRP designations and aligned the primary endpoint with the FDA to CR “at any time,” and management says ongoing SAP discussions increase confidence toward approval.
• Management states the safety database (the largest in the space at 125 patients) is sufficient and reports tolerability as near “best‑in‑class” with treatment discontinuations around 1–2%.
• They emphasize strong commercial fit in community urology: a non‑viral therapy with simple storage/handling, short clinic administration potentially by APP/staff, favorable buy‑and‑bill economics, and pricing flexibility to maximize market value.
• Company reports a cash runway into the second half of 2028, expects a potential approval in 2027, and plans interim 12‑month data updates (Q2 conference and H2), supporting a near‑term BLA path.

enGene Stock Performance

Shares of enGene stock opened at $6.99 on Tuesday. The company’s fifty day moving average is $9.54 and its 200 day moving average is $8.09. enGene has a twelve month low of $2.65 and a twelve month high of $12.25. The stock has a market cap of $468.26 million, a price-to-earnings ratio of -3.02 and a beta of -0.29. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.09.

Hedge Funds Weigh In On enGene

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Siren L.L.C. bought a new stake in shares of enGene during the 4th quarter valued at about $30,126,000. Janus Henderson Group PLC bought a new stake in enGene in the 4th quarter valued at about $17,110,000. Millennium Management LLC raised its stake in enGene by 7,214.0% during the 4th quarter. Millennium Management LLC now owns 1,499,520 shares of the company’s stock worth $13,541,000 after buying an additional 1,479,018 shares during the period. MPM Bioimpact LLC grew its stake in enGene by 247.1% in the fourth quarter. MPM Bioimpact LLC now owns 1,840,898 shares of the company’s stock valued at $16,623,000 after acquiring an additional 1,310,599 shares during the period. Finally, Polar Capital Holdings Plc bought a new position in shares of enGene in the 4th quarter worth $10,321,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ENGN. Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th. UBS Group raised their price target on enGene from $4.00 to $10.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 12th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of enGene in a research report on Monday. Citizens Jmp increased their target price on enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 12th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of enGene in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.29.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.